Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）
- Status
- UNKNOWN
- Phase
- PHASE4
Clinical Trials Related to Anlotinib
Related studies linked through entity extraction aliases.
Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）
- Status
- COMPLETED
- Phase
- PHASE2
Anlotinib in Treatment of Recurrent Small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients
- Status
- UNKNOWN
- Phase
- PHASE2
Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin
- Status
- UNKNOWN
- Phase
- NA
Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Phase I Study of the Combination of Anlotinib With Gefitinib
- Status
- UNKNOWN
- Phase
- NA
A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
- Status
- UNKNOWN
- Phase
- PHASE2
Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel
- Status
- UNKNOWN
- Phase
- NA
Study of Anlotinib in Patients With Primary Malignant Bone Tumors
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3
- Status
- UNKNOWN
- Phase
- PHASE2
Anlotinib and Irinotecan for Ewing Sarcoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)
- Status
- COMPLETED
- Phase
- PHASE2
A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Anlotinib in Patients With Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics
- Status
- UNKNOWN
- Phase
- PHASE1
Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3